Logo image of RENB

LUNAI BIOWORKS INC (RENB) Stock Fundamental Analysis

USA - NASDAQ:RENB - US29350E1047 - Common Stock

1.42 USD
+0.15 (+12.16%)
Last: 9/30/2025, 8:00:02 PM
1.54 USD
+0.12 (+8.45%)
After Hours: 9/30/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, RENB scores 1 out of 10 in our fundamental rating. RENB was compared to 534 industry peers in the Biotechnology industry. RENB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RENB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RENB had negative earnings in the past year.
RENB had a negative operating cash flow in the past year.
In the past 5 years RENB always reported negative net income.
RENB had a negative operating cash flow in each of the past 5 years.
RENB Yearly Net Income VS EBIT VS OCF VS FCFRENB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of RENB (-57.15%) is comparable to the rest of the industry.
The Return On Equity of RENB (-76.11%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.15%
ROE -76.11%
ROIC N/A
ROA(3y)-83.86%
ROA(5y)-54.42%
ROE(3y)-100.89%
ROE(5y)-64.97%
ROIC(3y)N/A
ROIC(5y)N/A
RENB Yearly ROA, ROE, ROICRENB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

RENB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RENB Yearly Profit, Operating, Gross MarginsRENB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

RENB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RENB has been increased compared to 5 years ago.
Compared to 1 year ago, RENB has an improved debt to assets ratio.
RENB Yearly Shares OutstandingRENB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
RENB Yearly Total Debt VS Total AssetsRENB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RENB has an Altman-Z score of 1.34. This is a bad value and indicates that RENB is not financially healthy and even has some risk of bankruptcy.
RENB has a better Altman-Z score (1.34) than 62.94% of its industry peers.
RENB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACCN/A
RENB Yearly LT Debt VS Equity VS FCFRENB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

RENB has a Current Ratio of 0.13. This is a bad value and indicates that RENB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.13, RENB is doing worse than 96.46% of the companies in the same industry.
RENB has a Quick Ratio of 0.13. This is a bad value and indicates that RENB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of RENB (0.13) is worse than 96.28% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
RENB Yearly Current Assets VS Current LiabilitesRENB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

RENB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.96%, which is quite impressive.
EPS 1Y (TTM)59.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RENB Yearly Revenue VS EstimatesRENB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 0 0 0 0 0

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RENB. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RENB Price Earnings VS Forward Price EarningsRENB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RENB Per share dataRENB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RENB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUNAI BIOWORKS INC

NASDAQ:RENB (9/30/2025, 8:00:02 PM)

After market: 1.54 +0.12 (+8.45%)

1.42

+0.15 (+12.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-29 2025-09-29
Earnings (Next)11-12 2025-11-12
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap327.92M
Revenue(TTM)N/A
Net Income(TTM)-67275200
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.71
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS0.38
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -57.15%
ROE -76.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.86%
ROA(5y)-54.42%
ROE(3y)-100.89%
ROE(5y)-64.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 1.34
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)31.12%
Cap/Depr(5y)59.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.3%
OCF growth 3YN/A
OCF growth 5YN/A

LUNAI BIOWORKS INC / RENB FAQ

What is the fundamental rating for RENB stock?

ChartMill assigns a fundamental rating of 1 / 10 to RENB.


What is the valuation status for RENB stock?

ChartMill assigns a valuation rating of 0 / 10 to LUNAI BIOWORKS INC (RENB). This can be considered as Overvalued.


Can you provide the profitability details for LUNAI BIOWORKS INC?

LUNAI BIOWORKS INC (RENB) has a profitability rating of 1 / 10.


What is the financial health of LUNAI BIOWORKS INC (RENB) stock?

The financial health rating of LUNAI BIOWORKS INC (RENB) is 4 / 10.